Cranbury, NJ, July 1, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present a company overview at Cantor Fitzgerald's Inaugural Healthcare Conference. The presentation by Wayne Pisano, VaxInnate's president and chief executive officer, will take place on Wednesday, July 8, 2015 at 10:45 am ET at the Le Parker Meridien Hotel in New York City.
VaxInnate's presentation will include an update of corporate and clinical milestones, including the Company's recent reallocation of resources to support increased research and development efforts while maintaining momentum on the development of its lead seasonal influenza vaccine candidate, VAX2012Q, which entered a Phase 2 clinical study in June 2015.
VAX2012Q is VaxInnate's investigational recombinant quadrivalent seasonal influenza vaccine. Each vaccine component is fused to a flagellin protein, which acts as a toll-like receptor (TLR) ligand. The TLR class of proteins is known to activate the innate immune system, which in turn enhances the adaptive immune response to vaccines. In a Phase 1 study of 316 healthy adults aged 18-40, doses of VAX2012Q as low as 2 mcg per component were shown to be immunogenic, with mean seroprotection rates exceeding 90% for each of the four vaccine components at the day 21 clinic visit. The vaccine was generally well-tolerated, with mild to moderate arm pain the most commonly reported adverse event. In June 2015, VaxInnate initiated a Phase 2 study of safety and immunogenicity of VAX2012Q, including an active comparator, Fluzone® Quadrivalent, in healthy adults aged 18-64. Data is expected in the second half of 2015.
Powerful Vaccine Technology Platform
VaxInnate's technology platform is based on proprietary toll-like receptor (TLR) technology, which potentiates the immune response. The TLR technology genetically fuses vaccine antigens to the bacterial protein flagellin, and this sequentially triggers the innate and adaptive immune systems. Using this technology, vaccines can be produced using low-cost, highly scalable recombinant DNA techniques, thus avoiding many of the challenges of conventional vaccine production. This technology has the potential for production of significantly greater quantities of vaccine in rapid timeframes, with very low infrastructure costs.
VaxInnate is a privately held biotechnology company in Cranbury, NJ that is pioneering a breakthrough technology platform for use in developing novel and proprietary vaccines. Influenza vaccines manufactured using this technology have demonstrated excellent immunogenicity in the elderly population, a group that is typically less responsive to influenza vaccines. VaxInnate's vaccines focus on infectious diseases, including seasonal and pandemic influenza, Clostridium difficile and dengue. VaxInnate's ongoing studies of seasonal and pandemic flu vaccines are significantly funded under Contract No. HHSO100201100011C with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS).
To learn more about VaxInnate and to explore the company's technology platform, please visit the website at www.vaxinnate.com.